Tiny trial tests if diet can undo fatty liver in Low-Birth-Weight adults

NCT ID NCT05842850

First seen Jun 24, 2026 · Last updated Jun 24, 2026

Summary

This study looks at whether a 4-week low-calorie diet can reverse fatty liver disease in people who were born with low birth weight. Researchers will compare them to people born at normal weight, using MRI scans to measure liver fat before and after the diet. Only 8 participants are being enrolled, making this a very early, small-scale investigation.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NAFLD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Steno Diabetes Center Aarhus

    RECRUITING

    Aarhus, Denmark

    Contact Email: •••••@•••••

  • Steno Diabetes Center Copenhagen

    RECRUITING

    Herlev, Denmark

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

low-calorie diet (meal replacement)

What this could lead to

If successful, this could show that fatty liver linked to low birth weight can be reversed with diet, pointing toward targeted lifestyle interventions.

What could go wrong

This is a very small, early proof-of-principle study with only 8 participants. Results may not apply to the broader population, and the diet is short-term.

Conditions

The condition(s) this trial relates to.

Insulin Resistance metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.